Homepage038290 • KOSDAQ
add
Macrogen Inc
Vorige slotkoers
â‚©Â 16.200,00
Dag-range
â‚©Â 16.130,00 - â‚©Â 16.490,00
Jaar-range
â‚©Â 14.700,00 - â‚©Â 24.600,00
Beurswaarde
177,47Â mld. KRW
Gem. volume
27,80K
Koers/winst
-
Dividendrendement
-
Primaire beurs
KOSDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(KRW) | sep 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 33,00Â mld. | 2,20% |
Bedrijfskosten | 13,80Â mld. | 4,68% |
Netto inkomsten | -3,18Â mld. | -60,92% |
Netto winstmarge | -9,64 | -57,52% |
Winst per aandeel | — | — |
EBITDA | 2,21Â mld. | 47,21% |
Effectief belastingtarief | 1,20% | — |
Balans
Totale activa
Totale passiva
(KRW) | sep 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 24,60Â mld. | 8,61% |
Totale activa | 274,19Â mld. | 3,79% |
Totale passiva | 124,82Â mld. | 40,99% |
Totaal aandelenvermogen | 149,37 mld. | — |
Uitstaande aandelen | 9,98 mln. | — |
Koers-boekwaardeverhouding | 1,10 | — |
Rendement op activa | -0,54% | — |
Rendement op kapitaal | -0,70% | — |
Kasstroom
Nettomutatie in liquide middelen
(KRW) | sep 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -3,18Â mld. | -60,92% |
Operationele kasstroom | -2,08Â mld. | 50,99% |
Kasstroom uit beleggingen | -9,57Â mld. | -22,48% |
Kasstroom uit financiering | 6,73Â mld. | 594,06% |
Nettomutatie in liquide middelen | -4,51Â mld. | 58,99% |
Vrije kasstroom | -10,07Â mld. | 35,34% |
Over
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Opgericht
5 jun 1997
Website
Werknemers
519